Cibus (NASDAQ:CBUS) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Cibus (NASDAQ:CBUS) had its price objective raised by investment analysts at Jefferies Financial Group from $1.90 to $3.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Jefferies Financial Group’s target price indicates a potential upside of 40.85% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on CBUS. Weiss Ratings restated a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Cibus in a research report on Monday, December 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.00.

Cibus Stock Performance

Shares of Cibus stock opened at $2.13 on Wednesday. Cibus has a 12 month low of $1.09 and a 12 month high of $4.19. The firm has a market capitalization of $115.62 million, a P/E ratio of -0.71 and a beta of 1.62. The company has a current ratio of 0.72, a quick ratio of 0.72 and a debt-to-equity ratio of 1.37. The business has a fifty day simple moving average of $2.71 and a two-hundred day simple moving average of $1.94.

Cibus (NASDAQ:CBUS) last released its earnings results on Tuesday, March 17th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.01. Cibus had a negative net margin of 3,492.30% and a negative return on equity of 174.58%. The firm had revenue of $1.06 million for the quarter, compared to the consensus estimate of $1.64 million. On average, equities analysts forecast that Cibus will post -2.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cibus

Large investors have recently bought and sold shares of the business. Corient Private Wealth LLC purchased a new position in Cibus in the 4th quarter worth about $145,000. PACK Private Wealth LLC bought a new stake in shares of Cibus in the fourth quarter worth approximately $27,000. BDT Capital Partners LLC grew its stake in shares of Cibus by 1,899.7% in the fourth quarter. BDT Capital Partners LLC now owns 63,410 shares of the company’s stock worth $110,000 after acquiring an additional 60,239 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Cibus by 74.4% during the fourth quarter. Renaissance Technologies LLC now owns 69,400 shares of the company’s stock valued at $121,000 after purchasing an additional 29,600 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Cibus by 60.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company’s stock valued at $91,000 after purchasing an additional 19,717 shares during the last quarter. 33.81% of the stock is currently owned by institutional investors.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.